Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
1.770
+0.060 (+3.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Theraptc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 12, 2024
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
August 12, 2024
Via
Benzinga
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12
July 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference
July 24, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
July 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
June 28, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
June 22, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024.
Via
Talk Markets
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 20, 2024
Via
Benzinga
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
June 20, 2024
Via
Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
June 13, 2024
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
Via
InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
June 11, 2024
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential.
Via
InvestorPlace
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 10, 2024
Via
Benzinga
Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
June 07, 2024
Via
Benzinga
Esperion to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
May 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
May 20, 2024
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse...
Via
Benzinga
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
May 20, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
May 14, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
May 08, 2024
Via
AB Newswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
May 07, 2024
Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024...
Via
Benzinga
Exposures
Product Safety
Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today?
May 07, 2024
AgriFORCE Growing stock is falling hard on Tuesday after the company announced an offering for AGRI shares from stockholders.
Via
InvestorPlace
Why Is GreenPower Motor (GP) Stock Down 36% Today?
May 07, 2024
GreenPower Motor stock is down on Tuesday after the EV company priced a public offering for 1.5 million shares of GP stock.
Via
InvestorPlace
Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today?
May 07, 2024
Esperion Therapeutics stock is up on Tuesday with heavy trading of ESPR shares after the company beat EPS and revenue estimates in Q1.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 07, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
May 07, 2024
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday!
Via
InvestorPlace
Esperion Reports First Quarter 2024 Financial Results
May 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.